A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2025-10-21

Target enrollment:

Participant gender:

This study is a multi-center, non-randomized, single-arm, open clinical trial.

N/A

Hebei Senlang Biotechnology Inc., Ltd.

Hebei Medical University Fourth Hospital

Cyclophosphamide
Fludarabine